OSE Immunotherapeutics

Historical price data

OSE Immunotherapeutics is an integrated, clinical-stage biotechnology company focused on developing first-in-class immunotherapies for immuno-oncology and immuno-inflammation. Its core strategy is driven by three proprietary technology platforms designed to precisely modulate the immune system. The company's most significant near-term catalyst is the Phase 3 ARTEMIA trial for Tedopi® in non-small cell lung cancer, which has received two positive IDMC recommendations. OSE aims to build value through a diversified pipeline and strategic partnerships.

Three proprietary platforms: 1) T-cell activation via neo-epitopes for cancer vaccines, 2) Reprogramming of immunosuppressive tumor microenvironment cells, and 3) Dual modulation of T-effector and regulatory T-cells for immune tolerance in autoimmunity.

OSE faces intense competition from large pharma and biotech across its focus areas. In post-checkpoint NSCLC, Tedopi® must compete against chemotherapies and a pipeline of novel agents. In autoimmunity, OSE-127 enters crowded markets dominated by established biologics. Its platforms compete with well-funded rivals in bispecific antibodies and novel checkpoint inhibition.